Centessa IPO Presentation Deck
Morphogen-IX
Developing MGX292, a preclinical stage disease-modifying, protein-engineered variant of human bone morphogenetic protein 9
(BMP9), targeting the central causal pathway of pulmonary arterial hypertension (PAH)
Mission
Develop a disease-modifying, protein-
engineered variant of human BMP9 that is
designed to overcome deficiency in BMP9
signaling, reverse disease pathology, and
avoid undesired bone formation for
patients with PAH
De-risking data
75% of patients with a family history of
PAH have heterozygous
loss-of-function mutations in the bone
morphogenetic protein type 2 receptor
(BMPR2)
000
MORPHOGEN-IX
Mutations in BMPR2 are found in 15% to
40% of patients with idiopathic PAH
Market opportunity
~70,000 patients in North America, Europe
and Japan affected by PAH
The total global market for PAH is ~$6.0
billion per annum based on sales of
approved drugs
CENTESSA
25View entire presentation